HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Kayes, S. G. Articles by Colley, D. G. Search for Related Content PubMed Articles by Kayes, S. G. Articles by Colley, D. G.

Immunoregulation in Experimental Schistosomiasis: in Vitro Induction and Assay of Spleen Cell Suppressor Activity¹

From the Veterans Administration Medical Center, Research and Development Service and The Department of Microbiology, Vanderbilt University School of Medicine, Nashville, Tennessee 37203

Abstract

Spleen cells from normal CBA/J mice or mice infected with Schistosoma mansoni were exposed for 48 to 72 hr to either concanavalin A (Con A), soluble egg antigen (SEA), or soluble worm antigenic preparation (SWAP), treated with mitomycin C to prevent further DNA synthesis, and admixed with either normal or sensitized syngeneic spleen cells exposed to a concentration gradient of phytohemagglutinin (PHA) or SEA, respectively. Both nonspecific (by Con A) and "antigen-specific" (by SEA and SWAP in infected mice only) induction of suppression was observed when using PHA-induced blastogenesis as the final assay. The number of mice with inducible splenic suppressive activity and the degree of PHA suppression induced by exposure to SEA appeared to decline between 8 and 20 weeks of infection. In contrast, when the response of spleen cells from mice infected for 8 weeks to SEA served as the final assay, strong suppressive activity was induced from the spleen cells of all chronically infected mice (20 weeks of infection). This model permits parallel analysis of the induction of suppressor activity by nonspecific and schistosome antigen-specific signals during the course of this chronic, immunoregulated condition, schistosomiasis mansoni.

Footnotes

¹ This work was supported in part by the National Institutes of Health (NIAID, Grant AI 11289) under the auspices of the United States-Japan Cooperative Medical Science Program and the Research and Development Service of the Veterans Administration Medical Center, Nashville, Tenn. 37203.